Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.

ABSTRACT:

Background

Posaconazole is effective as primary antifungal prophylaxis of invasive fungal diseases in patients with acute myeloid leukemia.

Design and methods

The impact of primary antifungal prophylaxis administered during front-line chemotherapy for acute myeloid leukemia was evaluated by comparing 58 patients who received oral amphotericin B (control group) to 99 patients who received oral posaconazole (posaconazole group). The primary endpoint was the incidence of proven/probable invasive fungal diseases. Secondary endpoints included incidence of invasive aspergillosis, survival at 4 and 12 months after the diagnosis of acute myeloid leukemia and costs.

Results

Proven/probable invasive fungal diseases were documented in 51.7% of patients in the control group and i

SUBMITTER: Girmenia C 

PROVIDER: S-EPMC3347676 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature